Media Doctor Canada
  
Follow us on Twitter

Media

 

+

 

Doctor

 

Canada

"Antihistamine improves Alzheimer's symptoms"


CTV.CA

Source: CTV.CA

Published: 17 Jul 2022

Category: Pharmaceutical

Rating: (1½ stars)

what they said (Hover the mouse cursor over underlined words for more info)

An allergy drug that's been used in Russia since the 1980s is showing promise in the treatment of Alzheimer's disease, researchers say.

A study conducted in Russia found that Alzheimer's patients who took the drug Dimebon had significant improvement in thought processes over a 12-month period compared to patients who were given a placebo.

The researchers said that this is the first drug to yield year-long improvement in those with Alzheimer's...

The original article can be found at: http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20080717/alzheimers_drug_080717/20080717?hub=Health&s_name=

how did it rate? (more information)

Criteria Rating
Total Score 3 of 10
Availability of Treatment Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Not Satisfactory (?)
Costs of Treatment Not Satisfactory (?)
Evidence Not Satisfactory (?)
Quantification of Benefits of Treatment Not Satisfactory (?)
Harms of Treatment Not Satisfactory (?)
Sources of Information Not Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of Harms of Treatment Not Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

Despite the interesting subject matter and potential treatment implications, the article gave a cursory overview of Dimebon's ability to treat Alzheimer's patients. While alternative treatment options (i.e. Aricept and Exelon) were not mentioned or discussed, the single treatment draw-back was considered to be the unavailability of the product here in Canada. No potential side effects were addressed and the benefits of the treatment were not quantified but rather described as "substantial improvement." In addition, details of the study design (i.e. how patients were chosen and what constituted a "substantial improvement" in psychiatric and behavioral symptoms) were not described or reported.

The article carefully acknowledged that the preliminary use of Dimebon showed promising results and mentioned that further studies were required to deem it safe and effective. Having said that, the large gaps in the reported information may have been misleading for readers and offered a false sense of hope for those experiencing or dealing with Alzheimer's.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Organisation:
Email:
Comments: *
Copyright © Media Doctor Canada